Literature DB >> 17668999

Development of synthetic biodegradable microparticulate vaccines: a roller coaster story.

Pål Johansen, Julia M Martínez Gómez, Bruno Gander.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17668999     DOI： 10.1586/14760584.6.4.471

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


× No keyword cloud information.
  9 in total

Review 1.  Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes.

Authors:  Benjamin G Keselowsky; Chang Qing Xia; Michael Clare-Salzler
Journal:  Hum Vaccin       Date:  2011-01-01

2.  Synthetic vaccines: Immunity without harm.

Authors:  Abhinav P Acharya; Niren Murthy
Journal:  Nat Mater       Date:  2011-03       Impact factor: 43.841

3.  A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination.

Authors:  Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Michael A Collier; Rebekah Watkins-Schulz; Ning Cheng; Clément N David; Charles E McGee; Gregory D Sempowski; Ivo Shterev; Karen McKinnon; Eric M Bachelder; Kristy M Ainslie; Jenny P-Y Ting
Journal:  J Control Release       Date:  2017-11-21       Impact factor: 9.776

4.  Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists.

Authors:  Michael A Collier; Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Monica M Johnson; Andrew N Macintyre; Gregory D Sempowski; Eric M Bachelder; Jenny P-Y Ting; Kristy M Ainslie
Journal:  Mol Pharm       Date:  2018-10-15       Impact factor: 4.939

5.  Optimization of stability, encapsulation, release, and cross-priming of tumor antigen-containing PLGA nanoparticles.

Authors:  Shashi Prasad; Virginia Cody; Jennifer K Saucier-Sawyer; Tarek R Fadel; Richard L Edelson; Martin A Birchall; Douglas J Hanlon
Journal:  Pharm Res       Date:  2012-07-14       Impact factor: 4.200

6.  Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy.

Authors:  Shashi Prasad; Virginia Cody; Jennifer K Saucier-Sawyer; W Mark Saltzman; Clarence T Sasaki; Richard L Edelson; Martin A Birchall; Douglas J Hanlon
Journal:  Nanomedicine       Date:  2010-08-06       Impact factor: 5.307

Review 7.  Nanoparticle delivery systems in cancer vaccines.

Authors:  Yogita Krishnamachari; Sean M Geary; Caitlin D Lemke; Aliasger K Salem
Journal:  Pharm Res       Date:  2010-08-19       Impact factor: 4.580

8.  3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates.

Authors:  Sudhir Pai Kasturi; Mohammed Ata Ur Rasheed; Colin Havenar-Daughton; Mathew Pham; Traci Legere; Zarpheen Jinnah Sher; Yevgeny Kovalenkov; Sanjeev Gumber; Jessica Y Huang; Raphael Gottardo; William Fulp; Alicia Sato; Sheetal Sawant; Sherry Stanfield-Oakley; Nicole Yates; Celia LaBranche; S Munir Alam; Georgia Tomaras; Guido Ferrari; David Montefiori; Jens Wrammert; Francois Villinger; Mark Tomai; John Vasilakos; Christopher B Fox; Steven G Reed; Barton F Haynes; Shane Crotty; Rafi Ahmed; Bali Pulendran
Journal:  Sci Immunol       Date:  2020-06-19

9.  Considerations for Size, Surface Charge, Polymer Degradation, Co-Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases.

Authors:  Christopher J Genito; Cole J Batty; Eric M Bachelder; Kristy M Ainslie
Journal:  Adv Nanobiomed Res       Date:  2021-01-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.